Loading
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Latest quote
$2.66
−$0.06 · -2.21%
After-hours
$2.6554
−$0.0046 · -0.17%
Oct 8, 7:56 PM ET
Regular session · ET · Market data may be delayed.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Day range
Current $2.66
52-week range
Current $2.66
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
91
Deep Value
Sentiment
65
Bullish
Risk
71
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Day range
Current $2.66
52-week range
Current $2.66
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 129.42M USD | 99.6M USD | 83.57M USD | 72.05M USD | 67.45M USD |
| Cost of goods sold | 46.23M USD | 38.01M USD | 32.79M USD | 29.25M USD | 25.96M USD |
| Gross profit | 83.19M USD | 61.59M USD | 50.78M USD | 42.8M USD | 41.49M USD |
| Research and development | 6.33M USD | 6.02M USD | 4.96M USD | 4.83M USD | 3.83M USD |
| Selling, general, and administrative | 62.56M USD | 47.84M USD | 51.42M USD | 56.6M USD | 64.73M USD |
| Operating expenses | 68.89M USD | 53.86M USD | 56.38M USD | 61.43M USD | 68.56M USD |
| Interest income | 2.13M USD | 1.13M USD | 661K USD | 3K USD | — |
| Interest expense | — | — | — | — | 55K USD |
| Depreciation and amortization | 1.45M USD | 1.48M USD | 1.71M USD | 1.88M USD | 1.63M USD |
| Operating income | 14.3M USD | 7.73M USD | −5.6M USD | −18.63M USD | −27.07M USD |
| Net income | 17.38M USD | 8.55M USD | −4.94M USD | −16.54M USD | −27.13M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$10.33
288.35% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 13, 2016 | 1:3 | — | — |
Effective Apr 13, 2016
1:3
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
